254 related articles for article (PubMed ID: 12559811)
1. Vaccination with DNA encoding ORFF antigen confers protective immunity in mice infected with Leishmania donovani.
Sukumaran B; Tewary P; Saxena S; Madhubala R
Vaccine; 2003 Mar; 21(11-12):1292-9. PubMed ID: 12559811
[TBL] [Abstract][Full Text] [Related]
2. Leishmaniasis: current status of vaccine development.
Sukumaran B; Madhubala R
Curr Mol Med; 2004 Sep; 4(6):667-79. PubMed ID: 15357215
[TBL] [Abstract][Full Text] [Related]
3. Ubiquitin conjugation of open reading frame F DNA vaccine leads to enhanced cell-mediated immune response and induces protection against both antimony-susceptible and -resistant strains of Leishmania donovani.
Sharma A; Madhubala R
J Immunol; 2009 Dec; 183(12):7719-31. PubMed ID: 19933862
[TBL] [Abstract][Full Text] [Related]
4. Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis.
Stäger S; Smith DF; Kaye PM
J Immunol; 2000 Dec; 165(12):7064-71. PubMed ID: 11120835
[TBL] [Abstract][Full Text] [Related]
5. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
Melby PC; Yang J; Zhao W; Perez LE; Cheng J
Infect Immun; 2001 Aug; 69(8):4719-25. PubMed ID: 11447143
[TBL] [Abstract][Full Text] [Related]
6. Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections.
Ghosh A; Zhang WW; Matlashewski G
Vaccine; 2001 Oct; 20(1-2):59-66. PubMed ID: 11567746
[TBL] [Abstract][Full Text] [Related]
7. A heterologous prime-boost vaccination regimen using ORFF DNA and recombinant ORFF protein confers protective immunity against experimental visceral leishmaniasis.
Tewary P; Jain M; Sahani MH; Saxena S; Madhubala R
J Infect Dis; 2005 Jun; 191(12):2130-7. PubMed ID: 15898000
[TBL] [Abstract][Full Text] [Related]
8. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major.
Gurunathan S; Sacks DL; Brown DR; Reiner SL; Charest H; Glaichenhaus N; Seder RA
J Exp Med; 1997 Oct; 186(7):1137-47. PubMed ID: 9314562
[TBL] [Abstract][Full Text] [Related]
9. Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis.
Basu R; Bhaumik S; Basu JM; Naskar K; De T; Roy S
J Immunol; 2005 Jun; 174(11):7160-71. PubMed ID: 15905560
[TBL] [Abstract][Full Text] [Related]
10. Immunization with recombinant LD1 antigens protects against experimental leishmaniasis.
Dole VS; Raj VS; Ghosh A; Madhubala R; Myler PJ; Stuart KD
Vaccine; 2000 Oct; 19(4-5):423-30. PubMed ID: 11027804
[TBL] [Abstract][Full Text] [Related]
11. gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani.
Bhowmick S; Ravindran R; Ali N
Infect Immun; 2008 Mar; 76(3):1003-15. PubMed ID: 18195029
[TBL] [Abstract][Full Text] [Related]
12. Heterologous priming-boosting with DNA and vaccinia virus expressing kinetoplastid membrane protein-11 induces potent cellular immune response and confers protection against infection with antimony resistant and sensitive strains of Leishmania (Leishmania) donovani.
Guha R; Das S; Ghosh J; Naskar K; Mandala A; Sundar S; Dujardin JC; Roy S
Vaccine; 2013 Apr; 31(15):1905-15. PubMed ID: 23499564
[TBL] [Abstract][Full Text] [Related]
13. LmjMAPK10 offers protection against Leishmania donovani infection.
Kumar S; Zutshi S; Patidar A; Bodhale N; Roy S; Sarkar A; Saha B
Parasite Immunol; 2020 Feb; 42(2):e12687. PubMed ID: 31770453
[TBL] [Abstract][Full Text] [Related]
14. Intramuscular immunization with p36(LACK) DNA vaccine induces IFN-gamma production but does not protect BALB/c mice against Leishmania chagasi intravenous challenge.
Marques-da-Silva EA; Coelho EA; Gomes DC; Vilela MC; Masioli CZ; Tavares CA; Fernandes AP; Afonso LC; Rezende SA
Parasitol Res; 2005 Dec; 98(1):67-74. PubMed ID: 16261353
[TBL] [Abstract][Full Text] [Related]
15. A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice.
Mazumdar T; Anam K; Ali N
Vaccine; 2004 Mar; 22(9-10):1162-71. PubMed ID: 15003644
[TBL] [Abstract][Full Text] [Related]
16. Complete protection against experimental visceral leishmaniasis with complete soluble antigen from attenuated Leishmania donovani promastigotes involves Th1-immunity and down-regulation of IL-10.
Bhaumik SK; Naskar K; De T
Eur J Immunol; 2009 Aug; 39(8):2146-60. PubMed ID: 19593771
[TBL] [Abstract][Full Text] [Related]
17. Cationic solid-lipid nanoparticles are as efficient as electroporation in DNA vaccination against visceral leishmaniasis in mice.
Saljoughian N; Zahedifard F; Doroud D; Doustdari F; Vasei M; Papadopoulou B; Rafati S
Parasite Immunol; 2013 Dec; 35(12):397-408. PubMed ID: 23710803
[TBL] [Abstract][Full Text] [Related]
18. Immunostimulatory oligodeoxynucleotides are potent enhancers of protective immunity in mice immunized with recombinant ORFF leishmanial antigen.
Tewary P; Sukumaran B; Saxena S; Madhubala R
Vaccine; 2004 Aug; 22(23-24):3053-60. PubMed ID: 15297055
[TBL] [Abstract][Full Text] [Related]
19. Vaccination with Leishmania soluble antigen and immunostimulatory oligodeoxynucleotides induces specific immunity and protection against Leishmania donovani infection.
Tewary P; Pandya J; Mehta J; Sukumaran B; Madhubala R
FEMS Immunol Med Microbiol; 2004 Oct; 42(2):241-8. PubMed ID: 15364110
[TBL] [Abstract][Full Text] [Related]
20. Comparison of liposome based antigen delivery systems for protection against Leishmania donovani.
Bhowmick S; Mazumdar T; Sinha R; Ali N
J Control Release; 2010 Jan; 141(2):199-207. PubMed ID: 19818373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
